NCT01270386已完成2 期
A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 136
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 and ≤ 70 years of age
- •Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer.
- •At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan)
- •Have failed for 2 lines of chemotherapy including EGFR-TKI.
- •ECOG performance scale 0 -
- •Life expectancy of more than 3 months.
- •Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
- •More than 4 weeks after operation or radiotherapy
- •More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors
- •Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min,
- •signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.
排除标准
- •Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung cancer)
- •Pregnant or breastfeeding women
- •Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure
- •Any factors that influence the usage of oral administration
- •PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation.
- •Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3).
- •Long-term untreated wounds or fractures.
- •Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc.
- •Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed.
- •Abuse of alcohol or drugs
- •Less than 4 weeks from the last clinical trial
- •Treatment with VEGFR, PDGFR, sSRC-TKI before.
- •History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
研究组 & 干预措施
Apatinib
Experimental
Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
干预措施: apatinib (Drug)
Placebo
Placebo Comparator
Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
干预措施: placebo (Drug)
结局指标
主要结局
Progression free survival
时间窗: 8 weeks
次要结局
- Overall Survival safety(8 weeks)
- DCR(Disease control rate)(8 weeks)
- ORR(objective response rate)(8 weeks)
- QoL(quality of life)(8 weeks)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerAdvanced or Metastatic Gastric CancerNCT01512745Jiangsu HengRui Medicine Co., Ltd.267
Unknown
3 期
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Carcinoma, Non-Small-Cell LungNCT02332512Jiangsu HengRui Medicine Co., Ltd.417
已完成
2 期
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric CancerGastric CarcinomaNCT00970138Fudan University141
已完成
2 期
Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal CancerColorectal CancerNCT01531777Jiangsu HengRui Medicine Co., Ltd.40
Unknown
1 期
Study of Apatinib as an Inhibitor of Tumor AngiogenesisTumorNCT00633490Fudan University18